Clinical Trial Update: FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating SGN-15 in combination with docetaxel for advanced non-small cell lung cancer, with FDG-PET imaging endpoints. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SGN-15

Snippet

Sponsor: Seagen Inc. | Conditions: Non-Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED